AlanCartmellMD

PubMed

• 12 citations
  A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.
  James R. Berenson, Robert F. Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre, Roger M. Lyons, Wael A. Harb, Hesham Mohamed, Ali Nourbakhsh, Robert M. Rifkin> ;American Journal of Hematology. 2017 May 1
• CHAMPION-1: A Phase 1/2 Study of Weekly Carfilzomib and Dexamethasone for Relapsed or Relapsed and Refractory Multiple Myeloma
  James R Berenson, Dimitrios Tzachanis, Jesus G Berdeja, Alan Cartmell, Wael Harb, Roger M Lyons, Morton Coleman, Alberto Bessudo, Ralph Boccia, Richy Agajanian> ;Blood.
• 21 citations
  Corrigendum: Human gut Bacteroidetes can utilize yeast mannan through a selfish mechanism
  Fiona Cuskin, Elisabeth C. Lowe, Max J. Temple, Yanping Zhu, Elizabeth A. Cameron, Nicholas A. Pudlo, Nathan T. Porter, Karthik Urs, Andrew J. Thompson, Alan Cartmell,...> ;Nature. 2015 Apr 16
• 344 citations
  Human gut Bacteroidetes can utilize yeast mannan through a selfish mechanism
  Fiona Cuskin, Elisabeth C. Lowe, Max J. Temple, Yanping Zhu, Elizabeth A. Cameron, Nicholas A. Pudlo, Nathan T. Porter, Karthik Urs, Andrew J. Thompson, Alan Cartmell,...> ;Nature. 2015 Jan 8
• A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
  Berenson JR, Yellin O, Kazamel T, Hilger JD, Chen C, Cartmell A, Woliver T, Flam M, Bravin E, Nassir Y, Vescio R, Swift RA> ;Leukemia. 2012-07-01
• 72 citations
  The structure and function of an arabinan-specific alpha-1,2-arabinofuranosidase identified from screening the activities of bacterial GH43 glycoside hydrolases.
  Alan Cartmell, Lauren S. McKee, Maria J. Peña, Johan Larsbrink, Harry Brumer, Satoshi Kaneko, Hitomi Ichinose, Richard J. Lewis, Anders Viksø-Nielsen, Harry J. Gilbert...> ;The Journal of Biological Chemistry. 2011 Apr 29
• 55 citations
  Structural insights into a unique cellulase fold and mechanism of cellulose hydrolysis
  Joana L. A. Brás, Alan Cartmell, Ana Luísa Carvalho, Genny Verzè, Edward A. Bayer, Yael Vazana, Márcia A. S. Correia, José A. M. Prates, Supriya Ratnaparkhe, Alisdair ...> ;Proceedings of the National Academy of Sciences of the United States of America. 2011 Mar 29
• 34 citations
  Analysis of the structural and functional diversity of plant cell wall specific family 6 carbohydrate binding modules.
  D.W. Abbott, Elizabeth Ficko-Blean, van, Bueren, Al, Artur Rogowski, Alan Cartmell, Pedro M. Coutinho, Bernard Henrissat, Harry J. Gilbert, Alisdair B. Boraston> ;Biochemistry. 2009 Nov 3
• 19 citations
  Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well‐tolerated frontline regimen
  James R. Berenson, Ori Yellin, Donald Woytowitz, Marshall S. Flam, Alan Cartmell, Ravi K. Patel, Herb Duvivier, Youram Nassir, Benjamin Eades, Christina DiLauro Abaya,...> ;European Journal of Haematology. 2009 Jun 1
• 46 citations
  The Active Site of a Carbohydrate Esterase Displays Divergent Catalytic and Noncatalytic Binding Functions
  Cedric Montanier, V.A. Money, Virgínia M. R. Pires, James E. Flint, Benedita A. Pinheiro, Arun Goyal, José A. M. Prates, Atsushi Izumi, Henrik Stålbrand, Carl Morland,...> ;Plos Biology. 2009 Mar 31
• 70 citations
  The Cellvibrio Japonicus Mannanase Cjman26C Displays a Unique Exo-Mode of Action that is Conferred by Subtle Changes to the Distal Region of the Active Site.
  Alan Cartmell, Evangelos Topakas, Valérie M.-A. Ducros, Michael D. L. Suits, Gideon J. Davies, Harry J. Gilbert> ;The Journal of Biological Chemistry. 2008 Dec 5
• 4 citations
  Probing the β-1,3:1,4 glucanase, CtLic26A, with a thio-oligosaccharide and enzyme variants
  V.A. Money, Alan Cartmell, Catarina I. P. D. Guerreiro, Valérie M.-A. Ducros, Carlos M. G. A. Fontes, Harry J. Gilbert, Gideon J. Davies> ;Organic & Biomolecular Chemistry. 2008 Feb 21
• 56 citations
  Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant
  Thomas Grote, Julio Hajdenberg, Alan Cartmell, Susan Ferguson, Angela Ginkel, Veena Charu> ;The Journal of Supportive Oncology. 2006 Sep 1
• Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy...
  Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Gallagher S, Charu V> ;J. Clin. Oncol.. 2004-07-15
• 308 citations
  Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results o...
  Peter D. Eisenberg, Jazmin Figueroa-Vadillo, Rosalio Zamora, Veena Charu, Julio Hajdenberg, Alan Cartmell, Alberto Macciocchi, Steven M. Grunberg> ;Cancer. 2003 Dec 1
• Join now to see all